Chemomab Therapeutics Ltd. CMMB
1.53 USD +0.13 (+9.29%)
Regular-session close
1.53 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
1.39 Day range 1.58
1.00 52-week range 2.83
- YTD
- -7.27%
- 1 year
- -40.00%
News
globenewswire.com Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
globenewswire.com Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic…
benzinga.com CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of…
globenewswire.com Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
seekingalpha.com Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
benzinga.com Chemomab Therapeutics, Scipher Medicine Strike All-Stock Merger Agreement; Combined Entity Expected To Operate Under Scipher Medicine Name, SCIP Ticker On Nasdaq Chemomab Therapeutics (NASDAQ:CMMB) ("Chemomab") and Scipher Medicine Corporation ("Scipher"), a leader in transforming treatment through next-generation precision medicine, today announced that they
globenewswire.com Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.
benzinga.com 11 Health Care Stocks Moving In Thursday's Intraday Session Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
benzinga.com Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.31) by 22.58 percent. This is a 57.14 percent increase over losses…
globenewswire.com Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update —New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible…
benzinga.com Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.40) by 40 percent. This is a 62.5 percent increase over losses of…
globenewswire.com Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update 2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
globenewswire.com Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for…
defenseworld.net Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling…
globenewswire.com Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology — New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL…
globenewswire.com Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for…
globenewswire.com Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update —Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a…
globenewswire.com Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.
zacks.com Best Momentum Stocks to Buy for Oct. 23 PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
zacks.com New Strong Buy Stocks for Oct. 23: MQ, GES and More MQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.
globenewswire.com Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
globenewswire.com CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan as compounding crises threaten thousands of lives in Upper…
globenewswire.com Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update — Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique…
globenewswire.com Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is…
globenewswire.com Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis —Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential…- benzinga.com Earnings Scheduled For November 14, 2024
benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - benzinga.com Earnings Scheduled For March 7, 2024 Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
benzinga.com Earnings Scheduled For August 14, 2023 Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.- benzinga.com Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private…
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Earnings Scheduled For March 31, 2023 Companies Reporting Before The Bell • Pioneer Muni High Inc (NYSE:MAV) is likely to report quarterly earnings at $0.05 per share on revenue of $35.00 million.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday saw 825 companies set new 52-week lows.
benzinga.com Earnings Scheduled For August 12, 2022 Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.- benzinga.com Earnings Scheduled For May 12, 2022 Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
benzinga.com Earnings Scheduled For March 9, 2022 Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 173 companies reached new 52-week lows.